Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At American Society Of Clinical Psychopharmacology Annual Meeting
2024年5月21日 - 9:30PM
Ketabon GmbH (“Ketabon” or “the Company”), a joint venture
between HMNC Brain Health and Develco Pharma, announced
today the Company will present poster presentations at the American
Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking
place on May 28-31, 2024 at Miami Beach.
Dr. Hans Eriksson, Chief Medical Officer of Ketabon and HMNC
Brain Health, will elucidate details on topline results of its
Phase 2 trial with KET01, an oral ketamine treatment with minimal
side effects, showing rapid improvements in depression severity and
Ketabon’s comparative study between KET01 and intranasal SPRAVATO®,
the current FDA-approved ketamine formulation.
Presentation details are as follows:
Session: W16Poster: Comparison of Tolerability,
Safety, and Pharmacokinetics of Antidepressant Doses of Oral
Ketamine Prolonged Release Tablets (KET01) and Intranasal
Esketamine: A Randomized, Placebo-Controlled, Double-Blind,
Cross-Over TrialPresenter: Hans Eriksson, M.D., Ph.D., CMO at
KetabonDate & Time: Wednesday, May 29, 2024 from 11:15 am to 1
pm ET
Session: T17Poster: A Randomized
Placebo-Controlled Double-Blind Phase 2 Trial of Adjunctive KET01
(Oral Prolonged-Release Ketamine) for Treatment-Resistant
DepressionPresenter: Hans Eriksson, M.D., Ph.D., CMO at KetabonDate
& Time: Thursday, May 30, 2024 from 12:30 pm to 2:15 pm ET
Pharmaceutical Pipeline SessionTopic: Oral
Prolonged-Release Adjunctive Ketamine (KET01): Phase 2 Trial in
Treatment-Resistant Depression and Phase 1 Trial Comparing
Tolerability with Intranasal EsketaminePresenter: Hans Eriksson,
M.D., Ph.D., CMO at KetabonDate & Time: Thursday, May 30, 2024
at 3:00 pm ET
“We are honored to speak at the premier CNS drug development
gathering, where we'll be sharing KET01’s potential to
significantly simplify treatment and provide an option for care
beyond clinical settings, ensuring comfort and convenience for
patients at home,” said Dr. Hans Eriksson, Chief Medical Officer of
Ketabon and HMNC Brain Health. “As a company committed to
pioneering personalized therapies in psychiatry, we're deeply
grateful for the opportunity to continue advancing alternative
treatments for patients grappling with treatment-resistant
depression.”
For more information on the Ketabon program, please visit
https://www.ketabon.health/.
About the Ketabon
Program The Ketabon program, a joint venture between
HMNC Brain Health and Develco Pharma comprises an oral
prolonged-release formulation of ketamine for TRD (KET01) with
minimal dissociative side effects, that could make it the first
ketamine treatment for depression suitable for use at home. The
pharmacokinetic profile of the prolonged-release formulation could
significantly improve the risk profile and patient convenience, by
minimizing dissociative side effects compared to the currently
applied intravenous and intranasal ketamine therapies resulting in
a decreased need for monitoring under medical supervision. TRD
patients with insufficient response to standard antidepressants
represent close to 30% of an overall estimated number of 320
million patients worldwide suffering from major depressive
disorder. Clinical development of oral prolonged-release ketamine
could also be potentially expanded into other indications beyond
depression, such as anxiety, aggression, PTSD, and panic
disorder.
About HMNC Brain
Health HMNC Brain Health (HMNC Holding GmbH) is a
global precision psychiatry biopharma company headquartered in
Munich, Germany which is pioneering the development of personalized
therapies powered by predictive companion diagnostics, leading to
higher remission rates. The company develops a unique pipeline for
targeting both Major Depressive Disorder (MDD) and
Treatment-Resistant Depression (TRD). The company has presence in
both Germany and the U.S. and is backed by a renowned global VC,
several family offices, and a strategic healthcare investor. More
information at www.hmnc-brainhealth.com
About Develco PharmaDevelco
Pharma is a Swiss-German pharmaceutical company headquartered in
Pratteln, Switzerland, specializing in the development and
manufacture of orally administered modified, prolonged &
chrono-release drugs containing known active ingredients.
Established in 2006, today the company has a workforce of 130
employees. A state-of-the-art production facility for analgesics
and drugs for the treatment of other indications has been in
operation in Schopfheim, in Germany, since 2016. Develco identifies
and defines pharmaceutical products containing known active
ingredients and develops generic, hybrid, value-added, and
innovative formulations backed by clinical data for the delayed or
modified release of active ingredients. On the strength of its
experience and innovativeness, the company has emerged as an
internationally recognized provider of pharmaceuticals for the
treatment of several disease areas. The customer base of Develco
Pharma includes global pharmaceutical groups. The company has some
180 market approvals in all (products of different dosages) in
Europe, the US, Middle East, South Africa, Asia, and Australia.
More information at www.develco.ch
Media contacts (U.S.):
Anne Donohoe
+1212.896.1265
hmncbrain@kcsa.com